Nancy Whiting, Recludix Pharma CEO

Fol­low­ing Dupix­ent’s rise, Sanofi heads down­stream in im­munol­o­gy for $125M small mol­e­cule pact with Re­cludix

As Sanofi ex­pands the reach of its block­buster Dupix­ent, the French Big Phar­ma is look­ing to go fur­ther down­stream in the IL-13 and IL-4 space …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.